The Experts below are selected from a list of 879 Experts worldwide ranked by ideXlab platform

Daniel J. West - One of the best experts on this subject based on the ideXlab platform.

  • 2169-PUB: Premeal Consumption of a Small, Ready-to-Drink Whey Protein Shot Suppresses Postprandial Hyperglycemia in Adults with Type 2 Diabetes
    Diabetes, 2020
    Co-Authors: Kieran Smith, Guy S. Taylor, Lise Hoej Brunsgaard, Emma J. Stevenson, Kelly A. Bowden Davies, Erik Jensen, Mark Walker, Daniel J. West
    Abstract:

    Background: The consumption of large (∼50g) doses of whey protein [WP] before meals (i.e., preload) has been shown to improve postprandial glycemic [PPG] excursions in people with type 2 diabetes [T2D]. Yet, studies to date have not accounted for treatment palatability, the energy associated with large WP doses, or the burden allied with preload preparation, limiting its ecological translation. Herein, we examined the PPG responses to a mixed-meal tolerance test [MMTT] following prior consumption of a low dose of WP from a novel, pre-made shot in people with T2D. Methods: Nine adults with T2D (8M/1F; HbA1c 57.6±10.1 mmol∙mol) attended the laboratory on two occasions, ∼14d apart. After an overnight fast, subjects randomly consumed a bespoke, ready-to-drink WP (15g) or placebo [PLA] shot (100ml) 10min prior to a 4hr MMTT (387kcal; 58% CHO). At 4hr, a further shot was consumed 10min before an ad libitum lunch. Subjective appetite and preload palatability were assessed by visual analog scales. Interstitial glucose was measured throughout. Data (mean±SD) were analyzed by a two-way repeated measures ANOVA. Results: Compared to PLA, WP attenuated early [0-60min] (-48.9±35.9%; p=0.01) and total [0-240min] PPG area under the curve (-22.7±17.5%; p 0.05) and ad libitum energy intake were similar between trials (p=0.48). Both preloads were rated highly palatable. Conclusion: Consuming a small, bespoke WP shot lowers post-meal hyperglycemia in people with T2D without affecting satiety and satiation. We highlight the potential for small, contemporary WP beverages that encompass both glycemic benefit but also patient taste and convenience, which may have lasting clinical value beyond formal research studies. Disclosure K. Smith: None. G.S. Taylor: None. K.A. Bowden Davies: None. L.H. Brunsgaard: None. E. Jensen: Employee; Self; Arla Foods Ingredients. M. Walker: None. E.J. Stevenson: None. D.J. West: None. Funding Arla Foods Ingredients Group P/S

  • 2276-PUB: A Palatable, Novel Whey Protein Shot Attenuates Postprandial Glycemia in Lean and Centrally Obese Adult Males
    Diabetes, 2019
    Co-Authors: Kieran Smith, Guy S. Taylor, Nduka Okwose, Dean M. Allerton, Lise Hoej Brunsgaard, Emma J. Stevenson, Daniel J. West
    Abstract:

    Background: Consuming large doses of whey protein (WP) ∼30 minutes before high-glycemic load meals reduces postprandial glycemia (PPG). However, it is unclear if this effect is retained at smaller doses of WP, ingested at realistic times before typical meals. Moreover, as central obesity is associated with elevated PPG, WP may offer benefit in improving PPG within such individuals. We examined the PPG responses to breakfast following consumption of a small WP shot in centrally obese and lean males. Methods: In a randomized-crossover design, 7 lean (BMI 24.3±1.5; waist circumference 79.3±7.1 cm; waist/hip ratio [WHR] 0.83±0.04) and 9 centrally obese (34.6±1.9; 112.8±10.2 cm; 0.97±0.1) age-matched, adult males performed two 240 minutes mixed-meal tests, 7d apart. After an overnight fast, participants consumed either a 100ml ready-to-drink WP shot (15g Protein) or 100ml water (CON) 10 minutes before a typical breakfast meal. Interval blood samples were collected for the measurement of plasma glucose. Data (mean±SD) were analyzed by a mixed-design ANOVA and Pearson’s correlation with significance accepted as p≤0.05. Results: WP reduced early PPG AUC 0-60min by 22±9.3% and 13.1±10% in lean and obese males, respectively, vs. CON (p 0-60min following WP vs. lean (p=0.02) with no differences after CON (p=0.62). Total trial glucose AUC 0-240min was comparable between conditions in both groups (p>0.05). WP reduced peak PPG vs. CON (lean: -26.5±7% [p Conclusion: Consuming a palatable, ready-to-drink WP shot before breakfast attenuates early elevations in PPG and reduces hyperglycemia in lean and centrally obese males. Central obesity predicts the glucose lowering effect of WP and may limit its application in this group. Disclosure K. Smith: None. G.S. Taylor: None. N. Okwose: None. D.M. Allerton: None. L.H. Brunsgaard: Employee; Self; Arla Foods Ingredients. E.J. Stevenson: None. D.J. West: Research Support; Self; Arla Foods Ingredients, Dexcom, Inc. Funding Arla Foods Ingredients Group P/S

Kieran Smith - One of the best experts on this subject based on the ideXlab platform.

  • 2169-PUB: Premeal Consumption of a Small, Ready-to-Drink Whey Protein Shot Suppresses Postprandial Hyperglycemia in Adults with Type 2 Diabetes
    Diabetes, 2020
    Co-Authors: Kieran Smith, Guy S. Taylor, Lise Hoej Brunsgaard, Emma J. Stevenson, Kelly A. Bowden Davies, Erik Jensen, Mark Walker, Daniel J. West
    Abstract:

    Background: The consumption of large (∼50g) doses of whey protein [WP] before meals (i.e., preload) has been shown to improve postprandial glycemic [PPG] excursions in people with type 2 diabetes [T2D]. Yet, studies to date have not accounted for treatment palatability, the energy associated with large WP doses, or the burden allied with preload preparation, limiting its ecological translation. Herein, we examined the PPG responses to a mixed-meal tolerance test [MMTT] following prior consumption of a low dose of WP from a novel, pre-made shot in people with T2D. Methods: Nine adults with T2D (8M/1F; HbA1c 57.6±10.1 mmol∙mol) attended the laboratory on two occasions, ∼14d apart. After an overnight fast, subjects randomly consumed a bespoke, ready-to-drink WP (15g) or placebo [PLA] shot (100ml) 10min prior to a 4hr MMTT (387kcal; 58% CHO). At 4hr, a further shot was consumed 10min before an ad libitum lunch. Subjective appetite and preload palatability were assessed by visual analog scales. Interstitial glucose was measured throughout. Data (mean±SD) were analyzed by a two-way repeated measures ANOVA. Results: Compared to PLA, WP attenuated early [0-60min] (-48.9±35.9%; p=0.01) and total [0-240min] PPG area under the curve (-22.7±17.5%; p 0.05) and ad libitum energy intake were similar between trials (p=0.48). Both preloads were rated highly palatable. Conclusion: Consuming a small, bespoke WP shot lowers post-meal hyperglycemia in people with T2D without affecting satiety and satiation. We highlight the potential for small, contemporary WP beverages that encompass both glycemic benefit but also patient taste and convenience, which may have lasting clinical value beyond formal research studies. Disclosure K. Smith: None. G.S. Taylor: None. K.A. Bowden Davies: None. L.H. Brunsgaard: None. E. Jensen: Employee; Self; Arla Foods Ingredients. M. Walker: None. E.J. Stevenson: None. D.J. West: None. Funding Arla Foods Ingredients Group P/S

  • 2276-PUB: A Palatable, Novel Whey Protein Shot Attenuates Postprandial Glycemia in Lean and Centrally Obese Adult Males
    Diabetes, 2019
    Co-Authors: Kieran Smith, Guy S. Taylor, Nduka Okwose, Dean M. Allerton, Lise Hoej Brunsgaard, Emma J. Stevenson, Daniel J. West
    Abstract:

    Background: Consuming large doses of whey protein (WP) ∼30 minutes before high-glycemic load meals reduces postprandial glycemia (PPG). However, it is unclear if this effect is retained at smaller doses of WP, ingested at realistic times before typical meals. Moreover, as central obesity is associated with elevated PPG, WP may offer benefit in improving PPG within such individuals. We examined the PPG responses to breakfast following consumption of a small WP shot in centrally obese and lean males. Methods: In a randomized-crossover design, 7 lean (BMI 24.3±1.5; waist circumference 79.3±7.1 cm; waist/hip ratio [WHR] 0.83±0.04) and 9 centrally obese (34.6±1.9; 112.8±10.2 cm; 0.97±0.1) age-matched, adult males performed two 240 minutes mixed-meal tests, 7d apart. After an overnight fast, participants consumed either a 100ml ready-to-drink WP shot (15g Protein) or 100ml water (CON) 10 minutes before a typical breakfast meal. Interval blood samples were collected for the measurement of plasma glucose. Data (mean±SD) were analyzed by a mixed-design ANOVA and Pearson’s correlation with significance accepted as p≤0.05. Results: WP reduced early PPG AUC 0-60min by 22±9.3% and 13.1±10% in lean and obese males, respectively, vs. CON (p 0-60min following WP vs. lean (p=0.02) with no differences after CON (p=0.62). Total trial glucose AUC 0-240min was comparable between conditions in both groups (p>0.05). WP reduced peak PPG vs. CON (lean: -26.5±7% [p Conclusion: Consuming a palatable, ready-to-drink WP shot before breakfast attenuates early elevations in PPG and reduces hyperglycemia in lean and centrally obese males. Central obesity predicts the glucose lowering effect of WP and may limit its application in this group. Disclosure K. Smith: None. G.S. Taylor: None. N. Okwose: None. D.M. Allerton: None. L.H. Brunsgaard: Employee; Self; Arla Foods Ingredients. E.J. Stevenson: None. D.J. West: Research Support; Self; Arla Foods Ingredients, Dexcom, Inc. Funding Arla Foods Ingredients Group P/S

Emma J. Stevenson - One of the best experts on this subject based on the ideXlab platform.

  • 2169-PUB: Premeal Consumption of a Small, Ready-to-Drink Whey Protein Shot Suppresses Postprandial Hyperglycemia in Adults with Type 2 Diabetes
    Diabetes, 2020
    Co-Authors: Kieran Smith, Guy S. Taylor, Lise Hoej Brunsgaard, Emma J. Stevenson, Kelly A. Bowden Davies, Erik Jensen, Mark Walker, Daniel J. West
    Abstract:

    Background: The consumption of large (∼50g) doses of whey protein [WP] before meals (i.e., preload) has been shown to improve postprandial glycemic [PPG] excursions in people with type 2 diabetes [T2D]. Yet, studies to date have not accounted for treatment palatability, the energy associated with large WP doses, or the burden allied with preload preparation, limiting its ecological translation. Herein, we examined the PPG responses to a mixed-meal tolerance test [MMTT] following prior consumption of a low dose of WP from a novel, pre-made shot in people with T2D. Methods: Nine adults with T2D (8M/1F; HbA1c 57.6±10.1 mmol∙mol) attended the laboratory on two occasions, ∼14d apart. After an overnight fast, subjects randomly consumed a bespoke, ready-to-drink WP (15g) or placebo [PLA] shot (100ml) 10min prior to a 4hr MMTT (387kcal; 58% CHO). At 4hr, a further shot was consumed 10min before an ad libitum lunch. Subjective appetite and preload palatability were assessed by visual analog scales. Interstitial glucose was measured throughout. Data (mean±SD) were analyzed by a two-way repeated measures ANOVA. Results: Compared to PLA, WP attenuated early [0-60min] (-48.9±35.9%; p=0.01) and total [0-240min] PPG area under the curve (-22.7±17.5%; p 0.05) and ad libitum energy intake were similar between trials (p=0.48). Both preloads were rated highly palatable. Conclusion: Consuming a small, bespoke WP shot lowers post-meal hyperglycemia in people with T2D without affecting satiety and satiation. We highlight the potential for small, contemporary WP beverages that encompass both glycemic benefit but also patient taste and convenience, which may have lasting clinical value beyond formal research studies. Disclosure K. Smith: None. G.S. Taylor: None. K.A. Bowden Davies: None. L.H. Brunsgaard: None. E. Jensen: Employee; Self; Arla Foods Ingredients. M. Walker: None. E.J. Stevenson: None. D.J. West: None. Funding Arla Foods Ingredients Group P/S

  • 2276-PUB: A Palatable, Novel Whey Protein Shot Attenuates Postprandial Glycemia in Lean and Centrally Obese Adult Males
    Diabetes, 2019
    Co-Authors: Kieran Smith, Guy S. Taylor, Nduka Okwose, Dean M. Allerton, Lise Hoej Brunsgaard, Emma J. Stevenson, Daniel J. West
    Abstract:

    Background: Consuming large doses of whey protein (WP) ∼30 minutes before high-glycemic load meals reduces postprandial glycemia (PPG). However, it is unclear if this effect is retained at smaller doses of WP, ingested at realistic times before typical meals. Moreover, as central obesity is associated with elevated PPG, WP may offer benefit in improving PPG within such individuals. We examined the PPG responses to breakfast following consumption of a small WP shot in centrally obese and lean males. Methods: In a randomized-crossover design, 7 lean (BMI 24.3±1.5; waist circumference 79.3±7.1 cm; waist/hip ratio [WHR] 0.83±0.04) and 9 centrally obese (34.6±1.9; 112.8±10.2 cm; 0.97±0.1) age-matched, adult males performed two 240 minutes mixed-meal tests, 7d apart. After an overnight fast, participants consumed either a 100ml ready-to-drink WP shot (15g Protein) or 100ml water (CON) 10 minutes before a typical breakfast meal. Interval blood samples were collected for the measurement of plasma glucose. Data (mean±SD) were analyzed by a mixed-design ANOVA and Pearson’s correlation with significance accepted as p≤0.05. Results: WP reduced early PPG AUC 0-60min by 22±9.3% and 13.1±10% in lean and obese males, respectively, vs. CON (p 0-60min following WP vs. lean (p=0.02) with no differences after CON (p=0.62). Total trial glucose AUC 0-240min was comparable between conditions in both groups (p>0.05). WP reduced peak PPG vs. CON (lean: -26.5±7% [p Conclusion: Consuming a palatable, ready-to-drink WP shot before breakfast attenuates early elevations in PPG and reduces hyperglycemia in lean and centrally obese males. Central obesity predicts the glucose lowering effect of WP and may limit its application in this group. Disclosure K. Smith: None. G.S. Taylor: None. N. Okwose: None. D.M. Allerton: None. L.H. Brunsgaard: Employee; Self; Arla Foods Ingredients. E.J. Stevenson: None. D.J. West: Research Support; Self; Arla Foods Ingredients, Dexcom, Inc. Funding Arla Foods Ingredients Group P/S

Guy S. Taylor - One of the best experts on this subject based on the ideXlab platform.

  • 2169-PUB: Premeal Consumption of a Small, Ready-to-Drink Whey Protein Shot Suppresses Postprandial Hyperglycemia in Adults with Type 2 Diabetes
    Diabetes, 2020
    Co-Authors: Kieran Smith, Guy S. Taylor, Lise Hoej Brunsgaard, Emma J. Stevenson, Kelly A. Bowden Davies, Erik Jensen, Mark Walker, Daniel J. West
    Abstract:

    Background: The consumption of large (∼50g) doses of whey protein [WP] before meals (i.e., preload) has been shown to improve postprandial glycemic [PPG] excursions in people with type 2 diabetes [T2D]. Yet, studies to date have not accounted for treatment palatability, the energy associated with large WP doses, or the burden allied with preload preparation, limiting its ecological translation. Herein, we examined the PPG responses to a mixed-meal tolerance test [MMTT] following prior consumption of a low dose of WP from a novel, pre-made shot in people with T2D. Methods: Nine adults with T2D (8M/1F; HbA1c 57.6±10.1 mmol∙mol) attended the laboratory on two occasions, ∼14d apart. After an overnight fast, subjects randomly consumed a bespoke, ready-to-drink WP (15g) or placebo [PLA] shot (100ml) 10min prior to a 4hr MMTT (387kcal; 58% CHO). At 4hr, a further shot was consumed 10min before an ad libitum lunch. Subjective appetite and preload palatability were assessed by visual analog scales. Interstitial glucose was measured throughout. Data (mean±SD) were analyzed by a two-way repeated measures ANOVA. Results: Compared to PLA, WP attenuated early [0-60min] (-48.9±35.9%; p=0.01) and total [0-240min] PPG area under the curve (-22.7±17.5%; p 0.05) and ad libitum energy intake were similar between trials (p=0.48). Both preloads were rated highly palatable. Conclusion: Consuming a small, bespoke WP shot lowers post-meal hyperglycemia in people with T2D without affecting satiety and satiation. We highlight the potential for small, contemporary WP beverages that encompass both glycemic benefit but also patient taste and convenience, which may have lasting clinical value beyond formal research studies. Disclosure K. Smith: None. G.S. Taylor: None. K.A. Bowden Davies: None. L.H. Brunsgaard: None. E. Jensen: Employee; Self; Arla Foods Ingredients. M. Walker: None. E.J. Stevenson: None. D.J. West: None. Funding Arla Foods Ingredients Group P/S

  • 2276-PUB: A Palatable, Novel Whey Protein Shot Attenuates Postprandial Glycemia in Lean and Centrally Obese Adult Males
    Diabetes, 2019
    Co-Authors: Kieran Smith, Guy S. Taylor, Nduka Okwose, Dean M. Allerton, Lise Hoej Brunsgaard, Emma J. Stevenson, Daniel J. West
    Abstract:

    Background: Consuming large doses of whey protein (WP) ∼30 minutes before high-glycemic load meals reduces postprandial glycemia (PPG). However, it is unclear if this effect is retained at smaller doses of WP, ingested at realistic times before typical meals. Moreover, as central obesity is associated with elevated PPG, WP may offer benefit in improving PPG within such individuals. We examined the PPG responses to breakfast following consumption of a small WP shot in centrally obese and lean males. Methods: In a randomized-crossover design, 7 lean (BMI 24.3±1.5; waist circumference 79.3±7.1 cm; waist/hip ratio [WHR] 0.83±0.04) and 9 centrally obese (34.6±1.9; 112.8±10.2 cm; 0.97±0.1) age-matched, adult males performed two 240 minutes mixed-meal tests, 7d apart. After an overnight fast, participants consumed either a 100ml ready-to-drink WP shot (15g Protein) or 100ml water (CON) 10 minutes before a typical breakfast meal. Interval blood samples were collected for the measurement of plasma glucose. Data (mean±SD) were analyzed by a mixed-design ANOVA and Pearson’s correlation with significance accepted as p≤0.05. Results: WP reduced early PPG AUC 0-60min by 22±9.3% and 13.1±10% in lean and obese males, respectively, vs. CON (p 0-60min following WP vs. lean (p=0.02) with no differences after CON (p=0.62). Total trial glucose AUC 0-240min was comparable between conditions in both groups (p>0.05). WP reduced peak PPG vs. CON (lean: -26.5±7% [p Conclusion: Consuming a palatable, ready-to-drink WP shot before breakfast attenuates early elevations in PPG and reduces hyperglycemia in lean and centrally obese males. Central obesity predicts the glucose lowering effect of WP and may limit its application in this group. Disclosure K. Smith: None. G.S. Taylor: None. N. Okwose: None. D.M. Allerton: None. L.H. Brunsgaard: Employee; Self; Arla Foods Ingredients. E.J. Stevenson: None. D.J. West: Research Support; Self; Arla Foods Ingredients, Dexcom, Inc. Funding Arla Foods Ingredients Group P/S

Lise Hoej Brunsgaard - One of the best experts on this subject based on the ideXlab platform.

  • 2169-PUB: Premeal Consumption of a Small, Ready-to-Drink Whey Protein Shot Suppresses Postprandial Hyperglycemia in Adults with Type 2 Diabetes
    Diabetes, 2020
    Co-Authors: Kieran Smith, Guy S. Taylor, Lise Hoej Brunsgaard, Emma J. Stevenson, Kelly A. Bowden Davies, Erik Jensen, Mark Walker, Daniel J. West
    Abstract:

    Background: The consumption of large (∼50g) doses of whey protein [WP] before meals (i.e., preload) has been shown to improve postprandial glycemic [PPG] excursions in people with type 2 diabetes [T2D]. Yet, studies to date have not accounted for treatment palatability, the energy associated with large WP doses, or the burden allied with preload preparation, limiting its ecological translation. Herein, we examined the PPG responses to a mixed-meal tolerance test [MMTT] following prior consumption of a low dose of WP from a novel, pre-made shot in people with T2D. Methods: Nine adults with T2D (8M/1F; HbA1c 57.6±10.1 mmol∙mol) attended the laboratory on two occasions, ∼14d apart. After an overnight fast, subjects randomly consumed a bespoke, ready-to-drink WP (15g) or placebo [PLA] shot (100ml) 10min prior to a 4hr MMTT (387kcal; 58% CHO). At 4hr, a further shot was consumed 10min before an ad libitum lunch. Subjective appetite and preload palatability were assessed by visual analog scales. Interstitial glucose was measured throughout. Data (mean±SD) were analyzed by a two-way repeated measures ANOVA. Results: Compared to PLA, WP attenuated early [0-60min] (-48.9±35.9%; p=0.01) and total [0-240min] PPG area under the curve (-22.7±17.5%; p 0.05) and ad libitum energy intake were similar between trials (p=0.48). Both preloads were rated highly palatable. Conclusion: Consuming a small, bespoke WP shot lowers post-meal hyperglycemia in people with T2D without affecting satiety and satiation. We highlight the potential for small, contemporary WP beverages that encompass both glycemic benefit but also patient taste and convenience, which may have lasting clinical value beyond formal research studies. Disclosure K. Smith: None. G.S. Taylor: None. K.A. Bowden Davies: None. L.H. Brunsgaard: None. E. Jensen: Employee; Self; Arla Foods Ingredients. M. Walker: None. E.J. Stevenson: None. D.J. West: None. Funding Arla Foods Ingredients Group P/S

  • 2276-PUB: A Palatable, Novel Whey Protein Shot Attenuates Postprandial Glycemia in Lean and Centrally Obese Adult Males
    Diabetes, 2019
    Co-Authors: Kieran Smith, Guy S. Taylor, Nduka Okwose, Dean M. Allerton, Lise Hoej Brunsgaard, Emma J. Stevenson, Daniel J. West
    Abstract:

    Background: Consuming large doses of whey protein (WP) ∼30 minutes before high-glycemic load meals reduces postprandial glycemia (PPG). However, it is unclear if this effect is retained at smaller doses of WP, ingested at realistic times before typical meals. Moreover, as central obesity is associated with elevated PPG, WP may offer benefit in improving PPG within such individuals. We examined the PPG responses to breakfast following consumption of a small WP shot in centrally obese and lean males. Methods: In a randomized-crossover design, 7 lean (BMI 24.3±1.5; waist circumference 79.3±7.1 cm; waist/hip ratio [WHR] 0.83±0.04) and 9 centrally obese (34.6±1.9; 112.8±10.2 cm; 0.97±0.1) age-matched, adult males performed two 240 minutes mixed-meal tests, 7d apart. After an overnight fast, participants consumed either a 100ml ready-to-drink WP shot (15g Protein) or 100ml water (CON) 10 minutes before a typical breakfast meal. Interval blood samples were collected for the measurement of plasma glucose. Data (mean±SD) were analyzed by a mixed-design ANOVA and Pearson’s correlation with significance accepted as p≤0.05. Results: WP reduced early PPG AUC 0-60min by 22±9.3% and 13.1±10% in lean and obese males, respectively, vs. CON (p 0-60min following WP vs. lean (p=0.02) with no differences after CON (p=0.62). Total trial glucose AUC 0-240min was comparable between conditions in both groups (p>0.05). WP reduced peak PPG vs. CON (lean: -26.5±7% [p Conclusion: Consuming a palatable, ready-to-drink WP shot before breakfast attenuates early elevations in PPG and reduces hyperglycemia in lean and centrally obese males. Central obesity predicts the glucose lowering effect of WP and may limit its application in this group. Disclosure K. Smith: None. G.S. Taylor: None. N. Okwose: None. D.M. Allerton: None. L.H. Brunsgaard: Employee; Self; Arla Foods Ingredients. E.J. Stevenson: None. D.J. West: Research Support; Self; Arla Foods Ingredients, Dexcom, Inc. Funding Arla Foods Ingredients Group P/S